Abstract: SA-PO1077
Prevalence of Albuminuria in US Adults with Obesity and Its Possible Impact on CKD Screening: A Cross-Sectional Analysis of NHANES Data, 2003-2020
Session Information
- CKD: Epidemiology, Risk Factors, and Prevention - 3
October 26, 2024 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: CKD (Non-Dialysis)
- 2301 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention
Authors
- Batool, Aisha, Medical College of Wisconsin, Milwaukee, Wisconsin, United States
- Habib, Hafsa, Medical College of Wisconsin, Milwaukee, Wisconsin, United States
- Chaudhry, Shahzad, Advocate Aurora Health Inc, Milwaukee, Wisconsin, United States
- El-Meanawy, Ashraf, Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Background
About 37 million US adults are reported to have CKD and those with proteinuric CKD have higher mortality. There's no agreement on whether albuminuria screening is beneficial for the general US population or individuals who are obese. Our study aims to determine a correlation between obesity and albuminuria, and b) relationship of albuminuria with mortality.
Methods
This study utilized data from NHANES 2003-2020 with urine albumin and creatinine ratio>30 (uACR) to identify albuminuria and BMI>30 to identify obesity. The final dataset comprised 59,717 adults. Employing a series of multivariable-adjusted regression models, we assessed the IDR to evaluate the association between uACR and obesity with overall mortality.
Results
The demographic analysis indicated that among those with albuminuria, 40% were obese, 57% women, and 61% were low-middle income category based on FPIR. Within the albuminuria group, 24% were diabetics, with an average A1C level of 6.1%. Additionally, 52% of those with albuminuria were identified as hypertensive and only 26% were utilizing RAAS blockade. Logistic regression model weighted results by albuminuria and obesity when adjusted for socioeconomic risk factors OR of 1.36 with 95% CI 1.23-1.50 p value <.001. The age-adjusted mortality rate exhibited an upward trend across albuminuria group.
Conclusion
In a nationally representative US adult population, we have observed robust, progressively increasing corelation between albuminuria and obesity. We have also observed that individuals with albuminuria have higher likelihood of all-cause mortality within all segments of sex, race or ethnicity, and concurrent health conditions. Our study underscores the underutilization of albuminuria-reducing agents in approximately 75% of individuals with albuminuria. This emphasizes a missed opportunity for screening a potentially at-risk population of obese individuals who could benefit from therapies aimed at reducing albuminuria.